The importance of metabolic and proteomic analyses in identifying treatment pathways for cancer patients
11 set 2023 ·
43 min. 11 sec.
Iscriviti gratuitamente
Ascolta questo episodio e molti altri. Goditi i migliori podcast su Spreaker!
Scarica e ascolta ovunque
Scarica i tuoi episodi preferiti e goditi l'ascolto, ovunque tu sia! Iscriviti o accedi ora per ascoltare offline.
Descrizione
Listen in as the CEO of TD2, Dr. Stephen Gately, sits down with Dr. Ed Weinstein, co-founder and CEO of Panome Bio, to discuss their important research on metabolomics and...
mostra di più
Listen in as the CEO of TD2, Dr. Stephen Gately, sits down with Dr. Ed Weinstein, co-founder and CEO of Panome Bio, to discuss their important research on metabolomics and proteomics. Gain insights into new screening technology for important metabolic and proteomic changes that occur in response to new drugs in development for cancer patients.
mostra meno
Informazioni
| Autore | Industry Dive's studioID |
| Sito | - |
| Tag |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
